C4 Therapeutics appoints Stephen Fawell to board of directors

C4 Therapeutics (CCCC) announced the continued evolution of its Board of Directors with the appointment of Stephen Fawell, Ph.D. as a director. With this appointment, Malcolm Salter has decided to retire from the Board of Directors after nearly a decade of service. Fawell has nearly 35 years of drug discovery experience spanning oncology, virology and other disease areas to successfully advance multiple investigational new drugs into clinical trials and ultimately achieve regulatory approval. Most recently, he spent more than a decade at AstraZeneca (AZN) as vice president, head of oncology small molecule drug discovery.